Texas MPN Workshop 2020 | COVID-19 and MPN

John Mascarenhas, MD, of the Icahn School of Medicine at Mount Sinai, New York, NY, outlines the the impact of COVID-19 on the treatment and management of patients with myeloproliferative neoplasms (MPNs), including reducing nosocomial infection risk in myelofibrosis patients, changes in clincial trial enrollment, as well as highlighting a role of ruxolitinib in this indication. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).